Merrimack Pharmaceuticals, Inc.

Palleon Pharmaceuticals Inc.

Lihui Xu

Alexey Alexandrovich Lugovskoy

Jonathan Basil Fitzgerald

Sharlene Adams

Neeraj Kohli

Bryan Johnson

Jason Baum

Lizhi Cao

Li Peng

The invention relates generally to recombinant human sialidases and recombinant sialidase fusion proteins, wherein the sialidase optionally contains one or more mutations compared to wild-type human sialidase, e.g., a substitution, deletion, or addition of at least one amino acid. The invention also provides antibody conjugates including a sialidase and an antibody or a portion thereof. The invention further relates to methods of using the sialidase fusion proteins or antibody conjugates for treating cancer.

Recombinant human sialidases, sialidase fusion proteins, and methods of using the same

Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.

Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies

Monospecific and bispecific anti-IGF-1R and anti-ERBB3 antibodies

Provided are bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3.

Bispecific anti-IGF-1R and anti-ErbB3 antibodies

Growing community of inventors

Chestnut Hill, MA, United States of America

Lihui Xu